Assessment of Wall Thickness in Hypertrophic Cardiomyopathy



Status:Completed
Conditions:High Cholesterol, Cardiology, Orthopedic
Therapuetic Areas:Cardiology / Vascular Diseases, Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:2/7/2019
Start Date:October 2014
End Date:July 25, 2017

Use our guide to learn which trials are right for you!

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and
prognostic importance given its known association with sudden cardiac death. However, data
regarding comparison of imaging modalities for this key measurement is lacking. This study
seeks to compare assessment of maximum wall thickness between clinically indicated
echocardiography (with and without contrast) and clinically indicated cardiac magnetic
resonance imaging.

Patients receiving clinically indicated echocardiograms and cardiac magnetic resonance
imaging at Mayo Clinic will be eligible.

Inclusion Criteria:

1. Clinically and echocardiographically defined hypertrophic cardiomyopathy.

2. Clinically indicated transthoracic echocardiography as part of the medical evaluation.

3. No contradiction to administration of ultrasonic echocardiography contrast.

4. Planned clinically indicated cardiac magnetic resonance imaging as part of medical
evaluation.

5. No contraindication to cardiac magnetic resonance imaging (such as cochlear implants,
central nervous system aneurysm clips and other implanted medical devices).

6. Age 18 years and older

Exclusion Criteria:

1) Insufficient image quality for determination of maximal wall thickness.
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials